Investor Presentaiton
Investor Presentation
First six months of 2018
Slide 6
Sales growth of 4% measured in local currencies mainly
driven by Victoza®, OzempicⓇ and SaxendaⓇ
Sales as reported - first six months of 2018
Other
Growth
disorders biopharmaceuticals
(4%)
(22%)
%
Haemophilia
6%
(10%) 9%
Obesity 3%
35%
81%
Growth break down - first six months of 2018
Local currencies
Long-acting insulin¹
Premix insulin²
Fast-acting insulin³
Human insulin
Total insulin
Growth
Share of growth
(3%)
(17%)
1%
3%
2%
9%
1%
4%
0%
(1%)
Diabetes care
(5%)
GLP-14
14%
77%
Other diabetes care5
2%
2%
Total diabetes care
4%
78%
Obesity (SaxendaⓇ)
50%
29%
Diabetes care and obesity total
5%
106%
Haemophilia
(2%)
(6%)
Growth disorders
5%
7%
Other biopharmaceuticals?
(18%)
(7%)
Biopharmaceuticals
(1%)
4%
(6%)
100%
Sales of DKK 54.3 billion (5%)
changing
diabetes
Total
1 Comprises Tresiba®, XultophyⓇ and LevemirⓇ: 2 Comprises RyzodegⓇ and NovoMix®
3 Comprises Fiasp® and NovoRapidⓇ; 4 Comprises VictozaⓇ and OzempicⓇ
5 Primarily NovoNorm® and needles; 6 Comprises NovoSeven®, NovoEight®
NovoThirteenⓇ and Refixia®; 7 Primarily Vagifem® and Activelle®View entire presentation